Spinal Muscular Atrophy: Avery's Bucket List Blog Raises Awareness Of The …
NEW YORK, April 3, 2012 /PRNewswire via COMTEX/ — The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM's Multi-Analyte Profiling (MAP) technology platform.
By Sandra Fish Dinakar Singh, chief executive officer of TPG-Axon Capital Management, discusses his daughter Arya's genetic disease and how it led him to establish and fund the Spinal Muscular Atrophy Foundation. You've probably never heard of Spinal
(NASDAQ:RGEN) said Wednesday that in a phase 1 study, its experimental treatment for patients with spinal muscular atrophy was well tolerated. Spinal muscular atrophy is a neuromuscular disease that affects about 20000 people in Europe and the United
Repligen licensed RG3039 in 2009 from Families of Spinal Muscular Atrophy (FSMA), a patient advocacy organization that funded and directed the preclinical development of RG3039 with an investment of more than $13
(NASDAQ:RGEN) said Wednesday that in a phase 1 study, its experimental treatment for patients with spinal muscular atrophy was well tolerated. Spinal muscular atrophy is a neuromuscular disease that affects about 20000 people in Europe and the United





